Scynexis Stock Price, News & Analysis

SCYNEXIS, Inc. (NASDAQ: SCYX) has announced that CFO Eric Francois will present at Ladenburg Thalmann’s virtual Healthcare Conference on July 14, 2021, from 11:00 to 11:25 AM ET. This presentation will highlight the company’s innovative medicines aimed at combating drug-resistant infections, particularly their lead asset, ibrexafungerp. The company recently received FDA approval for BREXAFEMME (ibrexafungerp tablets) on June 1, 2021. The conference webcast will be accessible for three months on the SCYNEXIS website.

SCYNEXIS announced stock options grants for four new employees totaling 18,100 shares at an exercise price of $7.36, aligning with the closing price on June 30, 2021. The options, part of the 2015 Inducement Award Plan, vest over four years, promoting employee retention. This initiative aims to attract talent in the biotech sector, focusing on innovative antifungal treatments.

SCYNEXIS is advancing ibrexafungerp, a drug targeting drug-resistant fungal infections, with FDA approval for BREXAFEMME on June 1, 2021.

SCYNEXIS has announced an update for the commercial launch of BREXAFEMME (ibrexafungerp), the first FDA-approved antifungal in over 20 years, specifically for vaginal yeast infections. The launch call is set for June 29, 2021, at 12 PM ET, featuring key presentations from management and Dr. Michael L. Krychman. BREXAFEMME offers a new treatment option for vulvovaginal candidiasis (VVC) and is contraindicated during pregnancy. This innovative drug demonstrates a favorable safety profile and efficacy against various Candida strains. For more details, visit www.brexafemme.com.

SCYNEXIS, Inc. (NASDAQ: SCYX) announced its participation in the BIO Digital International Convention from June 10-11 and June 14-18, 2021. Dr. Marco Taglietti, the company's CEO, will present the FDA-approved BREXAFEMME® (ibrexafungerp tablets) and discuss late-stage clinical trials for recurrent vaginal yeast infections and life-threatening fungal infections like Candida auris. Attendees can view the presentation ahead of one-on-one meetings starting June 14. SCYNEXIS focuses on developing innovative antifungal treatments aimed at tackling drug-resistant infections.

SCYNEXIS, Inc. has announced an extension of BREXAFEMME's exclusivity under the GAIN Act for a total of 10 years. The FDA's decision to grant 5 years of exclusivity is an addition to existing new chemical entity exclusivity. Moreover, BREXAFEMME is protected by a composition-of-matter patent, which is expected to last until 2035. The company plans to discuss commercial launch strategies on June 29. This antifungal drug is crucial for treating vulvovaginal candidiasis, especially against resistant strains of Candida.

SCYNEXIS, Inc. announced FDA approval for BREXAFEMME (ibrexafungerp), the first drug in a new antifungal class in over 20 years, specifically for treating vulvovaginal candidiasis (VVC). Following positive results from two Phase 3 studies, this oral treatment offers a favorable tolerability profile and is expected to launch commercially in partnership with Amplity Health in the latter half of 2021. With 14 years of patent protection, SCYNEXIS aims to establish a robust antifungal franchise, addressing the growing need for effective treatments against drug-resistant fungal infections.

SCYNEXIS (NASDAQ: SCYX) announced significant corporate developments and financial results for Q1 2021. The company secured approximately $35 million in non-dilutive funding, enhancing its cash runway into 2023. They anticipate FDA approval for ibrexafungerp (Brexafemme) to treat vaginal yeast infections by June 1, 2021. Phase 1 trial dosing for an IV formulation is underway. Q1 net loss decreased to $4.7 million from $7.0 million year-over-year. Selling, general & administrative expenses rose significantly, while research expenses decreased by 30%.

SCYNEXIS, Inc. (NASDAQ: SCYX) secured a $60 million term loan from Hercules Capital and Silicon Valley Bank to enhance its financial position ahead of the anticipated June 1 FDA approval for ibrexafungerp, an oral antifungal for vaginal yeast infections. This non-dilutive funding, along with a $93 million cash balance and other capital injections, extends SCYNEXIS’ cash runway into 2023. The loan disburses in four tranches, with $20 million already received and $10 million contingent upon FDA approval. This funding will support the launch of Brexafemme and the ongoing development of its antifungal pipeline.

SCYNEXIS, Inc. announced the appointment of Christine Coyne as Chief Commercial Officer, effective May 10, 2021. With over 30 years of experience in product commercialization, Coyne is expected to lead the upcoming U.S. launch of Brexafemme (ibrexafungerp), an oral antifungal for treating vulvovaginal candidiasis, pending FDA approval by June 1, 2021. The company aims to leverage her expertise in anti-infectives as they seek to broaden the product's label for treating severe infections.